Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Exelixis, Inc. (NASDAQ:EXEL), a $10.3 billion market cap company trading near its 52-week high, recently saw a significant stock sale by one of its top executives. Haley Patrick J., Executive Vice President of Commercial at Exelixis, sold 52,636 shares of the company’s common stock on February 24, 2025. The shares were sold at an average price of $36.98, amounting to a total transaction value of approximately $1.95 million. According to InvestingPro data, the stock has delivered an impressive 73% return over the past year.
Following this transaction, Patrick retains 303,310 shares of Exelixis stock directly, with additional indirect holdings through a spouse and a 401(k) plan. The sale was executed in multiple transactions, with prices ranging between $36.61 and $37.22 per share. InvestingPro analysis shows the company maintains excellent financial health with strong fundamentals, including more cash than debt on its balance sheet. Subscribers can access 15 additional ProTips and a comprehensive Pro Research Report for deeper insights into EXEL’s valuation and growth prospects.
In other recent news, Exelixis has been in the spotlight with several updates from analysts and ongoing studies. Truist Securities raised its price target for Exelixis to $43, citing optimism about the Phase 3 study of its drug Zanza in colorectal cancer patients without liver metastases. This adjustment follows encouraging data from the Phase 1 STELLAR-001 study, which has increased confidence in the drug’s potential approval. Meanwhile, Stifel has adjusted its price target for Exelixis to $36, maintaining a Hold rating, based on factors like anticipated operational expenditure growth moderation and the company’s share repurchase program.
JMP Securities maintained a Market Outperform rating with a $41 target, highlighting Exelixis’s fourth quarter 2024 revenue meeting expectations and the promising development of zanzalintinib. The focus on zanzalintinib’s potential in metastatic colorectal cancer has been a recurring theme, with analysts noting its prospects as a significant therapeutic option. Stifel also maintained a Hold rating with a $30 target earlier, taking into account the recent STELLAR-001 expansion cohort data and its implications for future trials.
These developments reflect a cautious yet optimistic outlook from analysts on Exelixis’s strategic direction and drug pipeline. The ongoing clinical trials and analyst ratings suggest a focus on the company’s long-term growth and potential in addressing unmet medical needs. Investors are closely watching Exelixis’s progress, particularly with its innovative treatments in the pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.